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Abstract
Reprogramming of somatic cells to different extents has been reported using different methods. However, this is normally
accompanied by the use of exogenous materials, and the overall reprogramming efficiency has been low. Chemicals and
small molecules have been used to improve the reprogramming process during somatic cell nuclear transfer (SCNT) and
induced pluripotent stem (iPS) cell generation. We report here the first application of a combined epigenetic and non-
genetic approach for reprogramming somatic cells, i.e., DNA methyltransferase (DNMT) and histone deacetylase (HDAC)
inhibitors, and human embryonic stem cell (hESC) extracts. When somatic cells were pretreated with these inhibitors before
exposure to hESC (MEL1) extracts, morphological analysis revealed a higher rate of hESC-like colony formation than without
pretreatment. Quantitative PCR (qPCR) demonstrated that pluripotency genes were upregulated when compared to those
of somatic cells or treated with hESC extracts alone. Overall changes in methylation and acetylation levels of pretreated
somatic cells suggests that epigenetic states of the cells have an effect on reprogramming efficiency induced by hESC
extracts. KnockOutserum replacement (KOSR
TM) medium (KO-SR) played a positive role in inducing expression of the
pluripotency genes. hESC extracts could be an alternative approach to reprogram somatic cells without introducing
exogenous materials. The epigenetic pre-treatment of somatic cells could be used to improve the efficiency of
reprogramming process. Under differentiation conditions, the reprogrammed cells exhibited differentiation ability into
neurons suggesting that, although fully reprogramming was not achieved, the cells could be transdifferentiated after
reprogramming.
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Introduction
Currently, there are four different strategies used to reprogram
somatic cells: i) somatic cell nuclear transfer (SCNT) [1], ii)
transduction of pluripotent genes into somatic cells [2], iii) somatic
cell fusion with pluripotent cells [3], and iv) pluripotent cell extract
mediated de-differentiation [4]. While SCNT and iPS cells have
drawn much attention, somatic cell reprogramming induced by
fusion with ESCs and by exposure to pluripotent cell extracts has
not been well studied.
The mechanism of reprogramming is not clear. However,
epigenetic changes have been known to be important as both global
and gene-specific DNA and histone modifications have been
observed in reprogramming in vitro [5]. DNA methylation status of
genes promoter regions is associated with transcriptional activities [6]
and research hasshownthatmouseESC genomesare lessmethylated
than those of somatic cells [7,8]. In human, it has also been shown
that hESCshave adistinct epigeneticsignature from somaticcells[9].
Higher levels of histone acetylation arefound in pluripotent cells than
in somatic cells [10]. Acetylation of H3 at Lysine 9 (H3K9) has been
recognized as one of the most important epigenetic markers, which,
when abundant in the promoter region of genes, represent an active
status and is correlated with gene expression [11,12].
DNA methylation is known to be catalyzed by DNMTs [13],
while histone deacetylation is catalyzed by HDACs [14]. Inhibitors
of these enzymes have been used in reprogramming experiments.
One of the DNMT inhibitors, 5-aza-29-deoxycytosine (5-aza-dC)
has been shown to silence imprinted gene expression in mouse
somatic cells by decreasing DNA methylation levels [15] and
others have used this demethylating agent to improve SCNT [16]
and iPS cell generation [17]. Similarly, when a HDAC inhibitor,
Trichostatin A (TSA) was applied to somatic cells, improvement in
nuclear cloning and iPS cell generation were also reported [18,19].
All-trans retinoic acid (ATRA) is known to bind to RA receptors
and activate Histone acetyltransferases (HAT) thus acts as an
indirect inhibitor of HDAC. It was demonstrated to induce
nucleosomal repulsion, chromatin relaxation, gene transcription
[20] and reduce cytosine methylation in of somatic cells [21].
Mouse embryonic stem cell (mESC) and the human embryonic
carcinoma cell (ECC) extracts have shown to reprogram somatic
cells to some extent [4], including reactivation of pluripotency
genes [22], chromatin remodeling [23], engraftment and trans-
differentiation of the reprogrammed cells in vivo [24]. However,
opposite results were also reported [25] and hESC extracts has not
been tested for reprogramming somatic cells. Furthermore, no
attempts to transform the knowledge obtained from other
reprogramming approaches, such as applying small molecules to
improve the event, has been reported. Thus we hypothesized
application of the above DNMT and HDAC inhibitors to somatic
cells, the chromosomes of the cells would decondense, and provide
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extracts to function.
In the present study, we report for the first time that hESC
extract induces reprogramming in human fetal fibroblasts (HFFs)
as determined by morphological changes and re-activation of ESC
specific makers. The reprogramming efficiency could be improved
by pre-treatment with DNMT and HDAC inhibitors. Repro-
grammed HFFs could be directly differentiated into DA neurons
when co-cultured with PA6 stromal cells. This reprogramming
approach without the use of gene transduction provides the
possibility for future therapeutic application. Lastly, our studies
have demonstrated that the p53/p21 pathway is activated during
reprogramming process under the culture conditions used here
and thus plays a negative role in hESC extract induced
reprogramming.
Results
Morphological changes in HFFs induced by hESC extract
treatment
The membrane of HFFs were first permeabilized with
Streptolysin-O (SLO). The cells were then exposed to either
hESC or HFF extracts (control) obtained from same number of
cells. After membrane resealing, the cells were cultured in
mTeSR
TM1 medium for 3 days and remarkable morphological
differences between treated and control samples were observed
(Figure 1A). The control cells exhibited no morphological
changes up to 14 days, whereas most of the hESC extract-treated
cells demonstrated a rounded cell morphology, resembling hESCs,
and started to form small clusters as early as 3 days post-treatment
(Figure 1A (b)). When manually transferred to feeder cells,
colonies with hESC-like morphology were formed (Figure 1A
(d)). The efficiency of colony formation was 1.260.3610
24%
from 6 independent experiments. Colony formation was not
observed among HFF extract-treated cells. To trace the origin of
the putative reprogrammed cells derived from HFFs after hESC
extract treatment and also to exclude the possibility of contam-
ination from hESCs, DNA microsatellite markers were analyzed
for HFFs, hESCs and hESC extract treated HFFs. As shown in
Table 1, the patterns of 15 short tandem repeats were matched
between hESC extract treated HFFs and parental HFFs, which
differed from hESCs. In addition, STR analysis showed a male
allele pattern for hESCs and female allele pattern for repro-
grammed HFFs and parental HFFs.
Changes in pluripotent/differentiation marker expression
patterns and epigenetic states in HFFs during hESC
extract induced reprogramming
Immunoblotting and immunofluorescent staining were per-
formed 7 days post hESC extract treatment. When hESC extracts
were loaded on a SDS-PAGE gel, no protein could be detected to
cross-react with b-actin, OCT4 or NANOG antibodies, indicating
the absence of these proteins. Thus, any protein detected should
be from the reprogrammed cells rather than from the hESC
extracts itself. OCT4 is strongly expressed in .90% of hESCs but
not in HFFs. Expression of OCT4 was detected in 23.364.3% of
HFFs treated with hESC extracts after 7 days of hESC extract
treatment (Figure 1B). NANOG remained undetectable in either
hESC or HFF extract-treated HFFs on day 7 (Figure S1). In
contrast, a differentiated cell marker LAMIN A/C was lost in
80.364.8% of HFFs after the hESC extract treatment
(Figure 1C). These data were confirmed by immunoblotting
analysis and NANOG protein band was also detected in hESC-
extract treated HFFs 7 days post-treatment (Figure 1D),
suggesting that HFFs were induced towards pluripotency while
differentiated characteristics were lost. Next, we determined
whether pluripotency-related genes OCT4, NANOG, SOX2, C-
MYC and KLF4 were transcriptionally induced by performing
qPCR. As shown in Figure 1E, 7 days after hESC extract
treatment, 3 to 7 fold increases of gene expression were detected in
HFFs after exposure to hESC extracts. Under the same condition,
no expression of the five genes was detected in hESC extracts.
To determine whether this hESC extract induced repro-
gramming was mediated by epigenetic modification of somatic
cell chromatin, DNA methylation and histone acetylation levels
were examined. No changes in 59-methylated cytosine (5 mC)
in the nucleoplasm were observed between hESC extract-
treated and non-treated HFFs (Figure S2). However, global
DNA methylation was found to be slightly lower in hESCs than
HFFs (Figure 2B). Global level of H3K9 acetylation in HFF
nuclei was increased by hESC extract treatment. As Figure 2A
shows, more than 90% of hESCs stained positively for histone
H3K9, while a smaller fraction of HFFs (22.965.1%) were
positively labeled, albeit with a weaker signal. This was not
altered by exposure of HFFs to its own extracts; however,
acetylation of histone H3K9 was restored after incubation with
hESC extracts and 43.169.3% of the total cells were positive
for H3K9. This increase in acetylation levels in hESC extract
treated HFFs was further confirmed by immunoblotting
analysis (Figure 2C).
Demethylation of OCT4 and NANOG promoters and up-
regulation of pluripotency-related genes in HFFs induced
by DNMT and HDAC inhibitors
To evaluate the effect of DNMT and HDAC inhibitors on HFF
nuclear re-modelling, 1 mM 5-aza-dC, 0.5 mM TSA and 0.1 mM
ATRA were supplemented in F-DMEM, KO-SR or DMEM
medium and cultured for 3 days. These concentrations of 5-aza-
dC, TSA and ATRA did not induce significant cell death or
inhibition of cell growth (Table S1). We examined the
methylation states around the promoter regions of five pluripo-
tency-related genes (OCT4, NANOG, SOX2, C-MYC and KLF4)b y
performing bisulfite sequencing analysis.
As shown in Figure 3A, The NANOG promoter region was
highly methylated in HFFs (95.3%) and completely unmethylated
in hESCs. A similar methylation pattern was observed in OCT4
examined region, where 93.3% of the CpG sites were methylated
in HFFs but only 11.3% were methylated in hESCs (Figure 3B).
DNMT and HDAC inhibitor treatment was shown to decrease the
methylation levels of both regions (73.4% and 83.3%, respective-
ly). When methylation levels in CpG islands of SOX2, c-MYC and
KLF4 were tested, the overall CpG methylation levels were found
to be lower than 5% for all three genes (Figure S3), indicating
that their expressions are not regulated through DNA methylation.
To gain further insight into the changes in pluripotency-related
gene expression patterns after the inhibitor treatment (72 hours),
qPCR was performed. When 5-aza-dC or TSA were applied,
pluripotency genes were not induced in HFFs (data not shown).
However, as shown in Figure 3C and 3D, OCT4, SOX2, c-MYC
and KLF4 was upregulated up to 6 fold in 5-aza-dC, TSA and
ATRA treated HFFs when compared to non-treated controls
(P,0.05). Interestingly, medium components were shown to affect
the induction of the genes in HFFs. Expression of OCT4, SOX2
and KLF4 was significantly higher in HFFs cultured in KO-SR
medium than in F-DMEM medium (P,0.05), except c-MYC, the
expression of the genes was higher in KO-SR culture than in
DMEM culture (P,0.05).
A New Reprogramming Method
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12297Figure 1. Morphological, protein and gene expression changes in HFFs induced by hESC extract treatment. (A) Morphology of HFFs
treated with its own extract (a) or hESC extract on day 3 (b), day 10 (c) and passage 2 (d). (B) OCT4 expression was induced in hESC extract-treated
HFFs on day 7. (C) LAMIN A/C was demolished in hESC extract-treated HFFs on day 7. (D) Imunoblotting analysis of NANOG, OCT4 and LAMIN A/C
expression on day 7. Lanes from 1 to 6 were loaded with proteins (2 mg) from HFFs, hESCs, hESC extract and HFF extract-treated HFFs, water and
hESC extracts. (E) Expression of OCT4, NANOG, SOX2, KLF4 and C-MYC were upregulated in hESC extract-treated HFFs after 7 days of hESC extract
treatment. The gene expression levels were normalized to the GAPDH and compared relative to gene expression in control HFFs. Error bar, S.D.,
***P,0.001 (n=3).
doi:10.1371/journal.pone.0012297.g001
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prior to hESC extract treatment
As early as 24 h after DNMT and HDAC inhibitor and hESC
extract combined treatment, differences in cell morphology could
be observed between control and treated HFFs. Without hESC
extract treatment, epigenetically modified HFFs in mTeSR
TM1
medium were spread out and exhibited characteristic fibroblast
morphology, whereas cells treated with the inhibitors and hESC
extracts appeared to be short and flattened, without cell-cell
contact (Figure 4A (a) and (b)). By day 3 (Figure 4A (c)), cell
clusters formed in the culture at an efficiency of 0.01760.009%
(from 3 independent experiments). The clusters increased in size,
and by 7 days post-treatment larger stem cell-like colonies were
formed (Figure 4A (d)). When these cells were manually dissected
and transferred to HFF feeder cells and cultured in KO-SR
medium, colonies resembling hESCs (Figure 4A (e)) were formed
at an efficiency of 1.35 to 2.07610
24% (from 5 independent
experiments).
Global epigenetic changes and expression of
pluripotency-related markers after combined treatment
To determine the overall methylation and acetylation status of
HFFs after DNMT/HDAC inhibitor and hESC extract treat-
ment, immunofluorescent staining and immunoblotting were
performed one week later. There was no change in DNA
methylation level in HFFs that were exposed to the inhibitors
with or without post hESC extract treatment (Figure S4) On the
contrary, the overall acetylation levels were increased (Figure 4B).
As shown in Figure 4C,5 2 64.5% and 6765.9% of HFFs
displayed intranuclear acetyl-histone H3 after chemical treatment
and combined treatment, respectively. Whereas there were less
HFFs positive for acetyl-histone H3 (3267.3%) with the labelling
signal at a lower intensity when compared to hESCs in which
more than 90% of the cells were positively stained. This suggested
a mild acetylation effect induced by the chemicals and/or hESC
extract. However, none of the treatment was able to significantly
increased histone acetylation level in HFFs (P,0.05).
Figure 5A shows .90% of hESCs were labeled positively for
NANOG and OCT4. In contrast, these two proteins were
undetectable in somatic HFFs. However, the labeling for both
transcription factors were obtained in HFFs after epigenetic
modification followed by hESC extract treatment. Additionally,
after 3 independent experiments we observed that 1562.8% and
3163.2% cells positively expressed NANOG and OCT4,
respectively.
Table 1. STR analysis of hESCs, HFFs and reprogrammed cells.
Locus MEL1 HFF
Reprogrammed
cells
D8S1179 13, 15 10, 14 10, 14
D21S11 30 27 27
D7S820 11, 12 8 8
CSF1PO 10, 14 10, 11 10, 11
D3S1358 15, 18 16 16
TH01 9.3 9 9
D13S317 11, 13 8, 9 8, 9
D16S539 12, 13 11, 13 11, 13
D2S1338 23 20, 25 20, 25
D19S433 14, 15 12, 16.2 12, 16.2
vWA 16 15, 18 15, 18
TPOX 8, 9 8 8
D18S51 12, 16 12, 13 12, 13
D5S818 11, 12 11, 12 11, 12
FGA 21 22 22
doi:10.1371/journal.pone.0012297.t001
Figure 2. Global epigenetic changes in HFFs 7 days after hESC extract treatment. (A) Acetylation level of H3K9 was increased in HFFs after
hESC extract treatment. (B) Immunoblotting analysis of 5-methyl cytosine. (C) Immunoblotting analysis of H3K9 acetylation levels. In A and C, lane 1
to 5 were loaded with proteins (2 mg) from hESCs, HFFs, HFFs treated with own extract or hESC extract, and negative control.
doi:10.1371/journal.pone.0012297.g002
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examined by qPCR 7 days post reprogramming treatment.
NANOG, OCT4 and SOX2 were more than 500 fold higher in
hESCs than in HFFs (Figure 5B and 5C), whereas c-MYC and
KLF4 were expressed 16 and 8 times higher in hESCs than HFFs,
respectively. These transcripts were not detected in hESC extracts,
confirming that the origin of the mRNAs was the cells rather than
the extracts. The trend of pluripotent gene reactivation was
observed after either chemical or hESC extract treatment alone.
However, it was only through the application of a combined
treatment that the genes: NANOG, OCT4, SOX2 and KLF4 resulted
in a significant upregulation (P,0.05). Interestingly, passaging of
the reprogrammed HFFs onto feeder layers seemed to play an
important role in improving reprogramming, since P2 cells showed
significant higher expression of all five tested genes than cells at P1
on matrigel (P,0.001). NANOG, OCT4 and SOX2 were expressed
15 to 40 fold higher in P2 cells than in control, while c-MYC and
KLF4 expression increased by 8 fold.
Activation of p53/p21 pathway in HFFs induced by
chemical and hESC extract treatments
Reprogramming is now known to be a stress process [26], and
the low efficiency of hESC extract induced reprogramming in the
current study seemed to support this point of view. Thus, it was
Figure 3. Effects of epigenetic modifications on HFFs. (A) Bisulfite sequencing of NANOG and (B) OCT4 promoter region. Black circles represent
methylated sites, white circles represent unmethylated sites. Global methylated cytosines are shown as %M. (C) qPCR analysis of NANOG, OCT4 and
SOX2 and (D) KLF4 and c-MYC expression in controls and HFFs with chemical treatment in different culture medium. The gene expression levels were
normalized to the GAPDH and compared relative to gene expression in control HFFs. Error bar, S.D.,
*P,0.05,
***P,0.001 (n=3).
doi:10.1371/journal.pone.0012297.g003
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12297Figure 4. Morphological and epigenetic changes of HFFs after inhibitor and/or hESC extract treatment. (A) Morphological changes of
HFFs elicited by DNMT and HDAC inhibitors and hESC extracts. HFFs in mTeSR (a) or with inhibitor treatment prior to hESC extract exposure on day 3
(b), day 7 (c), day 10 (d) and at passage 2 (e). (B) Immunoblotting analysis shows decrease in 5-methyl cytosine and increase in H3K9 acetylation levels
after combined treatment. Lanes 1 to 5 were loaded with proteins (2 mg) from HFFs, hESCs, inhibitor treated HFFs and combined treated HFFs. (C)
Immunostaining analysis shows increased H3K9 acetylation levels in HFFs after DNMT/HDAC inhibitor or combined treatment.
doi:10.1371/journal.pone.0012297.g004
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PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12297Figure 5. Protein and gene expression changes of HFFs after reprogramming treatment. (A) Pluripotency marker NANOG and OCT4 were
induced in HFFs after reprogramming. (B), (C) and (D) qPCR analysis of pluripotency-related gene and apoptotic gene expression in controls and
reprogrammed HFFs. The gene expression levels were normalized to the GAPDH and compared relative to gene expression in control HFFs. Error bar,
S.D.,
*P,0.05,
***P,0.001 (n=3).
doi:10.1371/journal.pone.0012297.g005
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role in cell growth and self-renewal in hESC extract induced
reprogramming. As shown in Figure 5D, control HFFs exposed
to their own cell extracts did not shown changes in expression level
of the apoptotsis-related genes. However, after reprogramming
and passaging onto irradiated feeder cells, hESC extract treated
cells at P2 exhibited significantly higher expression levels of TP53
and CDKN 1A compared to those of control HFFs (4 fold, P,0.05).
The expression of HDM2 was significantly lower than that in
control HFFs, whereas no difference of anti-apoptotic BCL2
expression was observed between reprogrammed cells and control
HFFs. CASP3 and CASP9 were expressed at two and four fold
higher in reprogrammed HFFs than those in control cells.
Coincidently, upon passaging of the reprogrammed cells, a further
upregulation of TP53, CDKN1A, CASP3 and CASP9 was observed,
which may have resulted in the cells inability to proliferate further.
Directed differentiation of reprogrammed HFFs into
neuronal cells
We next determined the differentiation capacity of these
reprogrammed cells into a neural lineage. The reprogrammed
fibroblasts were co-cultured on a monolayer of stromal cell-derived
inducing activity (SDIA) cells, PA6. The neuronal differentiation
was analyzed by examining morphological changes as well as
expression of neuronal specific genes and proteins. Morphological
appearance of the cells indicated the formation of neural lineages
upon directed differentiation. Furthermore, as shown in
Figure 6A, these reprogrammed cells acquired protein expression
specific to neuronal stem cells, neuronal precursors, immature
neurons, mature neurons, early DA neurons and also mature DA
neurons. PAX6 and SOX1 were detectable in differentiated cells
(both hESCs and reprogrammed) on day 7; NESTIN and TUJ
started to be expressed by differentiating cells from day 7 but the
density peaked on day 14. More mature neuronal makers MAP2
and TH were only stained after 3 weeks of differentiation.
Expression of neuronal marker genes in the differentiating cells
was analyzed by RT-PCR (Figure 6B). PAX6 was first detected
on day 6 in hESCs and on day 10 for reprogrammed HFFs. There
was a slight increase in this neural precursor gene during the two
weeks of differentiation and diminished by week four. Similarly,
definitive neural marker SOX1 showed a similar trend. However,
NESTIN was expressed during the whole neural differentiation (as
well as in undifferentiated hESCs). Similarly, TUJ and LMX1b
were also detected through the entire differentiation process. DA
neuron markers DAT and TH were expressed in differentiated
hESCs on day 10 and day 21, respectively. However, in
reprogrammed cells, DAT expression was only detectable from
day 21 and at a low level. Delayed expression of TH was also
observed in reprogrammed HFFs, which was later expressed from
day 28.
Discussion
The ultimate goal of reprogramming is to generate isogenic
pluripotent stem cells derived from adult somatic cells, so that
there is no graft rejection during transplantation into the host.
Extracts from pluripotent cells (i.e. mESCs and hECCs), Xenopus
[27,28] and mammalian [29] oocytes have been used to induce
somatic cell nuclear reprogramming [4,22,23,24,30]. However,
there has been no report of using hESC extracts for the same
purpose. In the current study, we demonstrated that human
somatic cells can be reprogrammed to a stem cell-like state by a
combined treatment with epigenetic modifying reagents (DNMT
and HDAC inhibitors) and hESC extracts. This was evidenced
by morphological changes, epigenetic changes and expression
of pluripotency-related genes and proteins during and after
reprogramming.
Morphological changes in the somatic cells transiently exposed
to hESC extracts were observed as early as 24 h post-treatment.
The formation of stem cell-like colonies was observed 10–14 days
post-treatment, which was similar to the time needed for
transcription factor-induced reprogramming [31]. Upregulation
of pluripotency markers and downregulation of differentiation
markers are indicators of somatic cell reprogramming. Oct4 is
required for pluripotency and reduction of Oct4 expression below
50% induces differentiation [32]. After incubation with hESC
extracts, a small percentage of somatic cells expressed OCT4,
indicating their dedifferentiation towards an embryonic state. At
the same time, LAMIN A/C expression, a marker of differentiated
cells [33] was decreased. Similar expression patterns for
pluripotent and differentiation genes were observed when somatic
cells were exposed to NCCIT, mESC or Xenopus oocyte extracts
[24,30,31]. However, in those studies, more than 50% of the total
somatic cells were reported to express the OCT4 protein, whereas
in the current study less than 30% of the treated HFFs were
positive for OCT4. This could be due to the difference between
extracts from different types of cells. The qPCR data confirmed
the upregulation of pluripotency associated genes, i.e. OCT4,
SOX2, c-MYC and KLF4 after hESC extract treatment, affirming
that the upregulation of these genes were made by components in
the hESC extracts, but not by the extract treatment.
Previous studies have demonstrated specific-gene promoter
demethylation and acetylation of Oct4 and Nanog, in somatic cells
after mouse ESC or human ECC extract treatment [23,24]. In our
study, we detected genome wide changes of demethylation and
acetylation induced by hESC extracts. These changes raise the
possibility that components in the hESC extracts may have similar
effects to other pluripotent cell extracts on modifying the
epigenetic status of somatic cells.
Oct4 and Nanog expressions are known to be regulated by
epigenetic mechanisms and can be altered by 5-aza-dC or TSA
[34,35]. While Oct4 was reported to be expressed in somatic cells
only when 5-aza-dC and TSA were applied, Nanog was unable to
be reactivated by these two chemicals in TS cells [34,35].
However, a more recent research reported that 5-aza-dC and
TSA are able to up regulate Oct4, Nanog and Klf4 in neurospheres
[36]. We found that neither DNMT nor HDAC inhibitor alone is
sufficient to increase the expression of pluripotency genes in HFFs
(data not shown). However, with the combination of 5-aza-dC,
TSA and ATRA, pluripotency-related genes were upregulated
compared to those in non-treated HFFs. Interestingly we found a
relationship between gene expression levels during reprogramming
in somatic cells and the culture media. The reason for this medium
effect is not known, however, the commercially purchased
KnockOut
TM serum replacement (KOSR
TM) (Invitrogen) is a
product with more-defined growth supplement (exact formulation
is not described) that reduces spontaneous differentiation in ESCs.
It has been reported that FBS-containing medium does not
support hESC growth whereas KO-SR medium is able to support
extended hESC growth [37]. KOSR
TM may also promote
reprogramming as suggested by previous reports showing that
compare to FBS, KOSR
TM can improve embryonic stem cell-line
derivation and iPSC generation [38,39]. Our bisulfite sequencing
analysis revealed partial demethylation of NANOG and OCT4
promoter regions in HFFs after DNMT and HDAC inhibitor
treatment, which are consistent with previous reports [34,35]. The
methylation status in OCT4 and NANOG promoter regions
together with the gene expression patterns indicated that the
A New Reprogramming Method
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may explain the reason why hESC culture medium is more
suitable for reactivating pluripotency-related genes.
We then combined epigenetic modification of HFFs with hESC
extract treatments and more defined evidence of reprogramming
was observed. As per Figure 4, reprogramming efficiency, colony
formation, pluripotent-associatedprotein expression indicated that
pre-treatment with epigenetic modifying agents of somatic cells is
beneficial for hESC extract-mediated reprogramming. The
pluripotency-related genes in reprogrammed HFFs were also
expressed at higher levels than epigenetically modified HFFs or
hESC extract-treated HFFs alone. In a recent report, where
mouse ESC extracts were used to induce somatic cell reprogram-
ming, researchers were not able to detect Oct4 expression until 6
weeks after treatment [30]. This could be another sign of
advantage of applying epigenetic modifying agents before inducing
reprogramming, since both OCT4 and NANOG were detected 5
days post-treatment in the current study.
The ability to self-renew indefinitely is one of the most defining
characteristics of ESCs. However, proliferation and self-renewal
properties of reprogrammed cells in this study were not
comparable with hESCs. The proliferation rate of colonies
generated was slower than hESCs and they could not be
maintained in culture with typical hESC morphology for extended
periods. Since reprogramming is a stressful process, it is possible
that the p53/p21 apoptotic pathway could play a negative role in
cell growth and self-renewal. Several groups have reported that
p53/p21 pathway serves as a barrier in nuclear reprogramming
during iPS cell generation [26,40,41,42]. As shown in Figure 5D,
there was a considerable increase in TP53 and CDKN1A
expressions in reprogrammed cells suggestive of p53/p21 pathway
activation, which may be induced by reprogramming and DNA
damage. Downstream genes of TP53 that are involved in cell
apoptosis (CASP3 and CASP9) [43] were also induced by
reprogramming treatment. HDM2 is a regulator of p53 and
mimicking p53 suppression in reprogramming [44]. Decreased
HDM2 levels further confirmed the negative effect of p53/p21
pathway on reprogramming. Although the mechanism of p53
activation in the reprogramming process is not clear, the initial
stress generated by chemicals and hESC extracts to induce
reprogramming can be a crucial one. Upregulation of apoptotic
genes after reprogramming in HFFs strongly support the
possibility that p53-dependent apoptosis is the main factor
decreasing cell viability and loss of self-renewal in the repro-
grammed HFFs. A more apparent explanation would be that the
reprogrammed cells have resided at an intermediate stage and
have not fully gained hESC properties since the expression levels
of pluripotency-related genes were significantly lower compared to
hESCs. Recent applications of the ROCK inhibitor Y-27632 in
enhancing survival of hESCs and generating iPS cells provide the
possibility to circumvent this problem [45,46]. However, the
reprogrammed cells were able to directly differentiate into
neuronal cells when co-cultured with PA6 cells. This testified the
differentiation ability of reprogrammed cells and suggested that
lineage reprogramming may have took place since complete
reversion to pluripotency did not occur. Most recently it was
reported that by manipulating culture conditions, endogenous
expression of stem cell genes were induced in somatic cells, but it
was a short-term induction [47]. Similarly, by changing the
microenvironment (applying ESC conditional medium and
epigenetic modifying molecules), iPS cells were generated from
rat progenitors [48]. Our data provide an alternative method of
reprogramming without introduction of genetic materials or
exogenous factors into somatic cells.
In summary, our study demonstrated that components of hESC
extract can modify the chromatin of HFFs and this nuclear
remodeling leads to reactivation of pluripotency-related genes and
repression of differentiation markers. Reprogramming can be
promoted by pre-treatment with DNMT and HDAC inhibitors,
which function through epigenetic modifications of the somatic
genome and the resulting cells possess the differentiation capacity
under appropriate conditions. However, upon extended culturing,
reprogrammed cells could not be maintained, most probably due
to p53/p21 pathway activation, which may function as a negative
regulator of the reprogramming process. Our research provides a
way of studying the features of reprogramming and the possibility
of identifying factors involved in reprogramming by analyzing the
components of the hESC extract. Application of small molecules
and hESC extracts may lead to efficient reprogramming without
altering the somatic genome. This approach also demonstrates
that in order to obtain a certain type of cell, it is not necessary to
revert cells back to a pluripotent state, followed by differentiation.
This approach to reprogramming provides a potential source of
patient-specific cells with possible application in regenerative
medicine.
Methods
Cells and cell culture
hESC line, MEL1 (CHEMICON, Millipore, USA) was
maintained on c-irradiated human fetal fibroblasts (HFFs) and
cultured in serum replacement (SR) medium, containing KO-
DMEM-high glucose, 20% SR, 2 mM L-glutamax, 0.1 mM non-
essential amino acid, 0.1 mM 2-mercaptoethanol, 16 insulin
transferring selenium, 25 U/ml penicillin, 25 mg/ml streptomycin
and 4 ng/ml basic fibroblast growth factor (bFGF). hESCs were
subcultured every 5–7 days using 0.05% Trypsin. HFFs were
derived from primary fetal skin tissue after therapeutic termination
of pregnancies and cultured in DMEM-high glucose medium
containing 10% fetal bovine serum (FBS), 25 U/ml Penicillin and
25 mg/ml Streptomycin. All reagents were from Invitrogen unless
otherwise stated.
For demethylating and acetylating treatment, P4 to P6 HFFs
were pre-cultured in F-DMEM to about 50% confluence before
being cultured in F-DMEM, KO-SR or DMEM medium
containing 1 mM 5-aza, 0.5 mM TSA and 0.1 mM ATRA for
72 hours or kept untreated for 3 days. Cell viability testing was
performed using fluorescent dyes 6-CFDA and propidium iodide
(PI).
PA6 murine stromal cells were maintained in F-MEM medium
containing minimum essential medium a (MEMa), 10%FBS,
25 U/ml penicillin and 25 mg/ml streptomycin. Medium was
changed every third day.
Preparation of hESC extract
Briefly, 4610
6 hESCs were treated with 0.1 mg/ml collagenase
IV and dispase. The resultant cells were washed twice with D-PBS
and once with lysis buffer (50 mM NaCl, 5 mM MgCl2, 100 mM
HEPES, 1 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfo-
nyl fluoride (PMSF) and 0.1% protease inhibitor cocktail (Sigma))
Figure 6. Expression of neuronal markers upon directed differentiation. (A) immunostaining of protein expression (B) RT-PCR analysis of
mRNA expression in hESCs and reprogrammed cells during the differentiation process.
doi:10.1371/journal.pone.0012297.g006
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the cell pellet of ice-cold cell lysis buffer was used to resuspend the
cells in 200 ml aliquots and were incubated on ice for 45 min.
Swelled ESCs were then subjected to sonication on ice with a
LABSONICH M ultrasonic homogenizer (Sartorius Stedim
Biotech, France) at 30% amplitude and 0.4-sec pulse cycle for
60–90 sec or until complete disruption of the cells and nuclei was
achieved by observation under the microscope. Cell lysates were
centrifuged at 15,0006g for 15 min at 4uC and the supernatant
was collected. The ESC extracts were then analyzed for
osmolariity and protein concentration. Cell extract from same
number of HFFs was prepared using the same protocol and was
used as a control. Both hESC and HFF extracts used for
reprogramming contained 30–35 mg/ml protein.
The toxicity of the extracts was assessed after extract
preparation. This was done by incubating 50,000 HFFs in 30 ml
extracts for 1 hour. Only cell extracts that did not induce apoptosis
(as determined by intact cell morphology under microscope) was
used for reprogramming.
HFF membrane permeabilization and hESC extract
treatment
HFFs were washed twice in ice-cold D-PBS followed by one
time wash in ice-cold HBSS by centrifuging at 5006g for 10 min.
Cell pellets were resuspended in appropriate volume of ice-cold
HBSS to make a concentration of 500,000 cells per reaction in
each 1.5 ml microcentrifuge tube on ice. Following centrifugation
at 5006g for 5 min at 4uC, cells were resuspended in ice-cold
HBSS with 350 ng/ml SLO and incubated for 2 min in a 37uC
water bath (50 mg/ml 10,000 Mr Texas red-conjugated dextran
was used to evaluate the efficiency of SLO treatment). The cells
were then incubated in a 37uC incubator horizontally for 50 min
with occasional tapping to maintain cells in suspension. After
permeabilization, cells were resuspended in 300 ml ESC extract
containing 1 mM ATP, 100 mM GTP, 25 mg/ml creatine kinase,
10 mM phosphocreatine and 1 mM NTP mix followed by
incubation at 37uC in a water bath for 1 h, with occasional
tapping.
After treatment, mTeSR
TM1 medium (StemCell Technologies)
supplemented with 2 mM CaCl2 was added to the cells and the
cells were transferred to Matrigel (BD Biosciences)-coated cell
culture plates for 2–4 h. After removing floating cells and medium,
fresh mTeSR
TM1 medium was added and the medium was
changed on a daily basis.
Directed differentiation of the reprogrammed cells into
neuronal cells
Differentiation experiments were designed according to previ-
ous published protocols [49,50]. Briefly, PA6 cells were plated in
tissue cultured plates coated with 0.1% Gelatin. After reprogram-
ming treatment and when the stem cell-like colonies had been of
reasonable sizes, the colonies were physically dissected and the
clumps were broken by pipetting. The cells were then added to
tissue culture plates coated with PA6 cell monolayer in
differentiation medium containing MEMa, 10% SR, 1 mM
sodium pyruvate, 0.1 mM non-essential amino acid and 0.1 mM
2-mercaptoethanol. hESCs were used as a positive control.
Differentiation medium was changed on day 4 and every second
day thereafter, until day 28.
Immunofluorescent staining
Cells were collected and fixed in 4% paraformaldehyde and
seeded onto poly-L-lysine coated slides (Menzel-Glaser) and
permeabilised with 0.2% v/v Triton-X-100 followed by blocking
with 10% normal serum in 3% bovine serum albumin (BSA) in
PBS. Relevant primary and secondary antibodies in 1% BSA were
then applied. Antibodies used included: Rabbit polyclonal to
OCT4 (Abcam), Rabbit polyclonal to NANOG (Abcam), Goat
polyclonal to LAMIN A/C (Santa Cruz Biotechnology), Mouse
monoclonal to 5-Methyl Cytidine (Abcam), Rabbit polyclonal to
Acetyl-Histone H3 (Lys9) (Cell signaling), Rabbit polyclonal to
PAX6 (Abcam), Rabbit polyclonal to SOX1 (Abcam), Mouse
monoclonal to NESTIN (Millipore), Rabbit polyclonal to TUJ
(Covance), Mouse monoclonal to MAP2 (Covance), Mouse
monoclonal to TH (R&D systems), Goat anti-Mouse IgG (FITC)
(Millipore), Goat anti- Rabbit IgG (FITC), Abcam, Rabbit anti-
Goat IgG (FITC) (Millipore), Goat anti-Rabbit IgG-H+L (Alexa
Fluor 594) (Invitrogen). Nuclei were stained with Prolong gold
anti-fade reagent with DAPI (Molecular probes, Invitrogen) before
being observed using a fluorescent microscope (Leica DMI3000).
Immunoblotting analysis
The cells were collected and lysed in RIPA buffer and the
proteins were separated via SDS-PAGE. Briefly, 2 mg of protein
were loaded onto 10% Tris-HCl gel (Biorad) and electrophoresis
was performed at 140 V for 40 min. The proteins were then
transferred to nitrocellulose membranes and blocked with 10%
normal serum in 3% BSA. This was followed by probing with
primary antibodies at 4uC overnight and secondary antibodies at
room temperature for 1 h. enhanced chemiluminescence (ECL) kit
(Amersham) and X-ray film (Hyperfilm ECL, Amersham) were
used to detect cross reactive proteins and standard developing and
fixing reagents (Kodak) was used to develop the exposed film.
Antibodies applied were Rabbit polyclonal to OCT4 (Abcam),
Rabbit polyclonal to NANOG (Abcam), Goat polyclonal to
LAMIN A/C (Santa Cruz Biotechnology), Sheep polyclonal to 5-
Methyl Cytosine (Novus Bio), Rabbit polyclonal to Acetyl-Histone
H3 (Lys9) (Cell signaling), Rabbit anti-goat IgG HRP (CALBIO-
CHEM), Goat anti-Mouse IgG HRP (Millipore), Goat anti-Rabbit
IgG HRP (Abcam), Rabbit anti-sheep IgG HRP, (Abcam).
RT-PCR analysis
Total RNA was extracted from whole cells using the Illustra
RNAspin Mini RNA Isolation Kit (GE healthcare). cDNA was
generated by standard reverse transcription using SuperScript III
First-Strand Synthesis System and Oligo (dT) primers (Invitrogen).
PCR was performed using Hybaid PCR express Thermocycler.
The PCR reaction mix contained the following components: 2 ml
106PCR Buffer (2Mg
2+), 0.6 ml 50 mM MgCl2, 0.4 ml1 0m M
dNTPs, 0.4 ml forward primer, 0.4 ml reverse primer, 0.2 ml Taq
DNA Polymerase and 15 ml PCR water to make a final reaction
volume of 20 ml. The reaction conditions were: 94uC for 2 min,
followed by 95uC for 30 sec, 59uC for 30 sec, 72uC for 30 sec (35
ceyles), then 72uC for 5 min. Primer pairs were: PAX6 forward
TCAGCACCAGTGTCTACCAACCAA, reverse ATCATAAC-
TCCGCCCATTCACCGA; SOX1 forward CAATGCGGG-
GAGGAGAAGTC, reverse CTCTGGACCAAACTGTGGCG;
NESTIN forward GGCAGCGTTGGAACAGAGGTTG, reverse
CTCTAAACTGGAGTGGTCAGGGCT; TUJ forward ACAA-
CGAGGCCTCTTCTCACAAGT, reverse TTTCACACTCC-
TTCCGCACCACAT; LMX1b forward AACTGTACTGCAAA-
CAAGACTACC, reverse TTCATGTCCCCATCTTCATCCT-
C; DAT forward AACTCCCAGTGTGCCCATGAGTAA, re-
verse AGCCAATGACGGACAGGAGAAAGT; TH forward
GTCCCCTGGTTCCCAAGAAAAGT, reverse TCCAGCTG-
GGGGATATTGTCTTC; b-ACTIN forward ACGGCATCGT-
CACCAACT, reverse AGGAAGGAAGGCTGGAAGAG.
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DNA was isolated using the DNeasy Blood & Tissue Kit
(Qiagen) and then treated with the EZ DNA Methylation-Gold
Kit
TM (Zymo Research) for bisulfite conversion. Converted DNA
was amplified by PCR using the primers listed below. The
annealing temperatures were 64uC for OCT4,5 7 uC for C-MYC,
59uC for SOX2 and 63uC for NANOG and KLF4. The PCR
products were then cloned into the pGEM-T Easy Vector
(Promega) system for sequencing. Primer pairs used were: OCT4
forward: TTGGGGGTTGGGTTAGGTTTTGAG, reverse: C-
TCCAACTTCTCCTTCTCCAACTTC; NANOG forward: TT-
GTTGTTTAGGTTGGAGTATAGTGG; reverse: ATAACC-
CACCCCTATAATCCCAATAA; SOX2 forward: GATGGTT-
TAGGAGAATTTTAAGATG, reverse: CRTAACTATCCAT-
ACRCTAATTCAC; KLF4 forward: GGATTTTTTGTTATA-
GAGGAGGTTT, reverse: TCTCCTAAACCTAAACTTTAT-
TCTC; c-MYC forward: GTAAATAGGAGGAGGGTTGAT-
GYG, reverse: CATCCAAATTAAACCACTAAACTC.
DNA finger printing
When ESC-like colonies could be identified, they were manually
dissected and DNA extracted using the DNeasy Blood & Tissue
Kit (Qiagen). hESC and HFF DNA was extracted at the same
time. 5–10 ml of DNA at 20–30 ng/ml for each sample were sent to
DNA Labs, Sydney IVF (Sydney, Australia) and DNA profiling
using the internationally recognized Identifiler system was
performed, followed by short tandem repeat (STR) analysis.
qPCR
Total RNA was extracted from whole cells using the Illustra
RNAspin Mini RNA Isolation Kit (GE healthcare). cDNA was
generated by standard reverse transcription using SuperScript III
First-Strand Synthesis System and Oligo (dT) primers (Invitrogen).
qPCR was performed on a RoterGene 3000 real-time PCR
machine. The reaction comprised 10 ml SensiMixPlus SYBR,
0.5 ml forward and reverse primer, 2 ml diluted DNA template and
7 ml PCR water. The reaction conditions were 95uC for 10 min,
followed by 40 cycles of 95uC for 15 sec, 60uC for 30 sec and
72uC for 20 sec. The relative expression of genes were normalized
against a house keeping gene GAPDH. Primer pairs were: OCT4
forward: TGGGCTCGAGAAGGATGTG, reverse: GCATA-
GTCGCTGCTTGATCG; NANOG forward: AGAAGGCCT-
CAGCACCTAC, reverse: GGCCTGATTGTTCCAGGATT;
SOX2 forward: ATGCACAACTCGGAGATCAG, reverse: TA-
TAATCCGGGTGCTCCTTC; KLF4 forward: CCCAATTA-
CCCATCCTTCCT, reverse: ACGATCGTCTTCCCCTCT-
TT; c-MYC forward: CTGGTGCTCCATGAGGAGAC, reverse:
CTCTGACCTTTTGCCAGGAG; TP53 forward; ACCAC-
CATCCACTACAACTACAT, reverse: ACAAACACGCACCT-
CAAAGC; CDKN1A forward: TGATTAGCAGCGGAACAAG,
reverse: AAACAGTCCAGGCCAGTATG; BCL2 forward: G-
CTCTAAAATCCATCCAG, reverse: CCTCTCCATCATCA-
ACTT; HDM2 forward: GGCTTTGATGTTCCTGATTG,
reverse: CTTTGTCTTGGGTTTCTTCC; CASP3 forward: TT-
TGAGCCTGAGCAGAGACA, reverse: CGTATGGAGAAA-
TGGGCTGT; CASP9 forward: CTAGTTTGCCCACACCC-
AGT, reverse: GGGACTGCAGGTCTTCAGAG; GADPH for-
ward: CATCCCTTCTCCCCACACAC, reverse: AGTCCCA-
GGGCTTTGATTTG.
Statistical analysis
Data presented as mean 6 SD from three independent
experiments. The statistics generated in this study were performed
using GraphPad Prism 5 (GraphPad Software, Inc). Significant
difference was analyzed by one-way ANOVA or two-way
ANOVA followed by Tukey-Kramer’s tests. The results were
considered significant when P values were less than 0.05.
Supporting Information
Table S1 Cell growth rate and viability of HFFs after treatment
with different concentrations of 5-aza-dC, TSA and ATRA.
Found at: doi:10.1371/journal.pone.0012297.s001 (0.66 MB TIF)
Figure S1 Immunofluorescent analysis of NANOG expression
in the cells. (a) hESCs, (b) HFFs, (c) HFF extract-treated HFFs and
(d) hESC extract-treated HFFs.
Found at: doi:10.1371/journal.pone.0012297.s002 (1.20 MB TIF)
Figure S2 Immunofluorescent analysis of global 5-methyl
cytosine level in the cells. (a) hESCs, (b) HFFs, (c) HFF extract-
treated and (d) hESC extract-treated HFFs.
Found at: doi:10.1371/journal.pone.0012297.s003 (1.18 MB TIF)
Figure S3 Bisulfite sequencing of CpG islands of SOX2, KLF4
and c-MYC.
Found at: doi:10.1371/journal.pone.0012297.s004 (1.39 MB TIF)
Figure S4 Immunofluorescent analysis of global 5-methyl
cytosine level in the cells. (a) hESCs, (b) HFFs, (c) HFFs after
DNMT/HDAC inhibitor treatment and (d) HFFs after combined
treatment.
Found at: doi:10.1371/journal.pone.0012297.s005 (1.17 MB TIF)
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